Evidence map›Paper›PMID 26362312›Full record

ArticleJournal of experimental & clinical cancer research : CR2015

DDR2 facilitates hepatocellular carcinoma invasion and metastasis via activating ERK signaling and stabilizing SNAIL1.

Binhui Xie, Weihao Lin, Junming Ye, Xiaonong Wang, Bing Zhang, Shiqiu Xiong, Heping Li, Guosheng Tan

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 98 citations in OpenAlex.

  1. Article
  2. Article
  3. Drug repositioning of regorafenib for renal cell carcinoma identifiesThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Binhui XieDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China.
Weihao LinDepartment of General Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Junming YeDepartment of Anesthesiology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China.
Xiaonong WangDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China.
Bing ZhangDepartment of Medical Imaging, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Shiqiu XiongDepartment of Biochemistry, University of Leicester, Leicester, LE1 9HN, UK.
Heping LiDepartment of Medical Imaging, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. lihp1979@163.com.
Guosheng TanDepartment of Medical Imaging, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. tgs918@163.com.
First Affiliated Hospital of Gannan Medical University · CNSun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CNUniversity of Leicester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral studies have found that DDR2 is up-regulated in many tumor types and facilitates tumor progression. However, the role of DDR2 in hepatocellular carcinoma (HCC) progression and its downstream signaling pathways remain unclear.

methodsDDR2 expression was assessed in several cell lines and 112 pairs of HCC and matched adjacent noncancerous liver tissues. Clinical significance of DDR2 in HCC was analyzed. Phosphorylated DDR2 (p-DDR2) expression was detected by immunoblotting to evaluate its correlation with DDR2. The effect of DDR2 on HCC cell migration and invasion were examined. Cycloheximide chase experiments were performed to detect the half-life of SNAIL1. Moreover, DDR2 expression was detected by immunohistochemistry to evaluate its correlation with SNAIL1. The regulatory effect of DDR2 on ERK signaling, SNAIL1, EMT, MT1-MMP and MMP2 was confirmed by immunoblotting. The effect of type I collagen on DDR2/ERK2/SNAIL1 signaling was assessed.

resultsDDR2 was more highly expressed in HCC than in non-HCC tissues. DDR2 overexpression was correlated with clinicopathological features of poor prognosis. Clinical analysis revealed that DDR2 is an independent prognostic marker for predicting overall survival and disease free survival of HCC patients. Overexpression of DDR2 is associated with p-DDR2 amplification. In vitro studies showed that DDR2 facilitates HCC cell invasion, migration and EMT via activating ERK2 and stabilizing SNAIL1. DDR2 can up-regulate MT1-MMP and MMP2 expression through ERK2/SNAIL1 signaling in HCC. Additionally, collagen I can induce DDR2/ERK2/SNAIL1 signaling activation in HCC cells.

conclusionsOur findings suggest that DDR2 plays an important role in promoting HCC cell invasion and migration, and may serve as a novel therapeutic target in HCC.

Indexed as

AdultCarcinoma, HepatocellularCell MovementCollagen Type IDiscoidin Domain ReceptorsDisease-Free SurvivalEpithelial-Mesenchymal TransitionFemaleHumansLiver NeoplasmsMaleMAP Kinase Signaling SystemMiddle AgedMultivariate AnalysisNeoplasm InvasivenessPrognosisCollagen Type IDiscoidin Domain ReceptorsReceptor Protein-Tyrosine KinasesReceptors, MitogenSNAI1 protein, humanSnail Family Transcription FactorsTranscription Factors

Identifiers

PMID26362312
PMCPMC4567819
OpenAlexW2136597063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.